Skip to main content

Table 2 Event rates in patients with cancer treated with certoparin or UFH

From: Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY

Pts with cancer at admission Certoparin UFH OR (95%CI) p-value*
  n/avail. % n/avail. %   
Thromboembolic events       
   Combined endpoint 5/111 4.50 7/116 6.03 0.73 (0.23-2.39) 0.6078
Proximal DVT 5/111 4.50 5/114 4.39 1.03 (0.29-3.65) 0.9656
Symptomatic non-fatal PE 0/129 0 1/128 0.78 - -
VTE related death 0/131 0 1/132 0.76 - -
   Distal DVT 10/101 9.90 7/106 6.60 1.55 (0.57-4.25) 0.3908
   Proximal or distal DVT 12/101 11.88 9/106 8.49 1.45 (0.58-3.61) 0.4213
   Symptomatic DVT 1/128 0.78 1/125 0.80 0.98 (0.06-15.78) 0.9866
   Death from any cause 2/131 1.53 6/132 4.55 0.33 (0.06-1.64) 0.1743
  1. Legend: Pts, patients; UFH, unfractionated heparin; DVT, deep venous thrombosis; PE, pulmonary embolism; OR, odds ratio; CI, confidence interval, * two-sided p-value for null-hypothesis: difference = 0 or odds ratio = 1.